Immunic (NASDAQ:IMUX) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Immunic (NASDAQ:IMUX – Get Rating) in a research note published on Thursday. The brokerage issued a sell rating on the stock.

Separately, Wedbush reissued an outperform rating and set a $5.00 target price on shares of Immunic in a research note on Tuesday, January 31st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, Immunic presently has an average rating of Hold and an average target price of $17.75.

Immunic Trading Up 5.1 %

Shares of IMUX stock opened at $1.86 on Thursday. The company has a market cap of $82.58 million, a price-to-earnings ratio of -0.51 and a beta of 1.86. The stock has a 50 day simple moving average of $1.61 and a 200-day simple moving average of $1.64. Immunic has a 12-month low of $1.11 and a 12-month high of $11.76.

Immunic (NASDAQ:IMUX – Get Rating) last issued its earnings results on Thursday, February 23rd. The company reported ($1.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.81). On average, equities analysts forecast that Immunic will post -2.11 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Immunic

A number of institutional investors and hedge funds have recently modified their holdings of IMUX. Charles Schwab Investment Management Inc. acquired a new stake in Immunic during the 1st quarter valued at $37,000. JPMorgan Chase & Co. grew its holdings in Immunic by 1,143.9% during the 4th quarter. JPMorgan Chase & Co. now owns 24,903 shares of the company’s stock valued at $35,000 after buying an additional 22,901 shares during the last quarter. Logos Global Management LP acquired a new stake in Immunic during the 1st quarter valued at $628,000. RTW Investments LP grew its holdings in Immunic by 11.2% during the 1st quarter. RTW Investments LP now owns 4,294,459 shares of the company’s stock valued at $6,399,000 after buying an additional 433,169 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Immunic during the 1st quarter valued at $129,000. Institutional investors and hedge funds own 60.67% of the company’s stock.

Immunic Company Profile

(Get Rating)

Immunic, Inc is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm’s products include IMU-838, IMU-935, and IMU-856.